Extracellular Vesicle Production via Sulfhydryl Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing extracellular vesicles (EVs) face challenges such as low yield, polydispersity, and difficulty in preserving their composition and biological functions, making them unsuitable for large-scale therapeutic delivery.
Innovation Solution
The method involves exposing mammalian cells to a solution containing sulfhydryl blocking reagents, such as paraformaldehyde and dithiothreitol, to generate EVs with controlled size and distribution, which are then purified and loaded with medicaments like doxorubicin for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cells are exposed to endosomal trafficking regulators, modified proteins, and external stressors to increase EV production, then production levels improve, but cellular activities are directly affected and composition and biological functions are difficult to preserve
Solution Approach 1:
The patent introduces sulfhydryl blocking reagents as an intermediary substance that mediates between the goal of high EV production and the need to preserve cellular integrity. These reagents block sulfhydryl groups to induce EV release without directly affecting cellular activities, thus resolving the contradiction between productivity and reliability
Solution Approach 2:
The patent replaces the mechanical/stress-based methods (external stressors, endosomal trafficking regulators) with a chemical approach using sulfhydryl blocking reagents. This substitution allows EV production to be stimulated without the harmful side effects of direct cellular intervention, maintaining both high productivity and biological function preservation
2Productivity
If cells are exposed to endosomal trafficking regulators and external stressors to increase EV production, then production levels improve, but the process becomes time- and labor-intensive
Solution Approach 1:
Sulfhydryl blocking reagents serve as a direct intermediary that rapidly induces EV release without requiring time-intensive cellular manipulation. The reagents work by directly blocking sulfhydryl groups to trigger EV shedding, eliminating the need for prolonged exposure to stressors or complex regulatory mechanisms
Solution Approach 2:
The patent employs sulfhydryl blocking reagents to rapidly skip through the time-consuming processes of endosomal trafficking regulation and cellular stress adaptation. The reagents directly induce EV release in a matter of hours rather than days, dramatically reducing the time and labor required for EV production
3Productivity
If conventional methods are used to produce EVs, then production can be achieved, but the EVs exhibit polydispersity and lack uniformity in size
Solution Approach 1:
The patent utilizes sulfhydryl blocking reagents to change the physical-chemical parameters of the cellular environment, specifically blocking sulfhydryl groups to induce uniform EV shedding. This parameter change results in EVs with consistent size and morphology, resolving the polydispersity issue while maintaining production capability
Solution Approach 2:
The patent achieves homogeneity in EV production by using sulfhydryl blocking reagents that uniformly affect all cells in the culture. The reagents create consistent conditions for EV release across the cell population, resulting in uniform EV size and composition without sacrificing productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid and scalable production of EVs with uniform size and stability, enhancing their potential for therapeutic delivery by achieving targeted immune responses and improved biodistribution.
Implementation Method 1
exposing at least one mammalian cell to a solution comprising sulfhydryl blocking reagents
Data Source
AI summary
Extracellular vesicles, their manufacture, and methods of treatment are described. Generally, extracellular vesicles can be generated by applying sulfhydryl blocking reagents on animal cells. Extracellular vesicles can be loaded with compounds for an intended use, such as, for example, loading an extracellular vesicle with a medicament to treat an animal. As described here, extracellular vesicles can be generated in a large scale and used for personalized treatments.